To include your compound in the COVID-19 Resource Center, submit it here.

FDA lifts clinical hold on Cellectis' CAR T candidate

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) said FDA lifted a clinical hold on Phase I testing of its chimeric antigen receptor (CAR) T cell candidate UCART123 to treat acute myelogenous leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Cellectis

Read the full 381 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE